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Abstract
Background: Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants.
We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational
age of <36 weeks) born between 2000 and 2006, and the use and impact of Palivizumab, a monoclonal antibody
that in randomized clinical trials has been shown to lessen the severity of RSV-related bronchiolitis.
Methods: Retrospective cohort study that linked data from four health administrative databases in the Lazio
region (a region of central Italy): the birth register, the hospital discharge register, and two ad-hoc databases that
record the doses of Palivizumab administered at two local health units.
Results: Among 2407 preterm infants, 137 had at least one hospitalization for bronchiolitis in the first 18 months
of life, an overall incidence rate of 4.70 per 100 person-years (95%CI: 3.98-5.56); similar incidence rates were
observed by calendar year. A multiple Poisson model showed that the following characteristics were associated
with higher incidence: younger age of the infant, the period between October-April, male gender, low Apgar score
at birth, low birth weight, and low maternal educational level. At least one dose of Palivizumab was administered
to 324 (13.5%) children; a dramatic increase from 2000 (2.8%) to 2006 (19.1%) (p < 0.01) was observed. Other
factors independently associated with more frequent Palivizumab use were older maternal age, Italian-born
mothers, female gender, low Apgar score, low birth weight, shorter gestational age, a diagnosis of broncho-
dysplasia, and the month of birth. It is of note that none of the 34 children with congenital heart disease were
prescribed Palivizumab. Performing several multiple Poisson models that also considered Palivizumab use as
covariate, although the point estimates were in agreement with previous clinical trial results, we did not find in
most of them a significant reduction for immunized children to be hospitalized for bronchiolitis.
Conclusion: In Italy the incidence of hospitalization for bronchiolitis, and its associated risk factors, are similar
to that found in other countries. Although Palivizumab use is associated with the most important characteristics
of severe prematurity, other aspects of its non-use in children with congenital heart disease, the age and the birth
country of the mother suggest the need for public health measures that can reduce these health disparities. Finally,
the estimated effectiveness of Palivizumab in routine practice, although not significant, confirms the results of
previous clinical trials, but its impact on modifying the temporal trend in this population is still negligible.
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Background
Bronchiolitis is an acute respiratory illness that particu-
larly affects infants and young children characterized by
coryza and sometimes low-grade fever that progress over
a few days to cough, tachypnoea, hyperinflation, chest
retraction, and widespread crackles, wheezes, or both [1].
The incidence of bronchiolitis has a seasonal trend with a
peak during the winter months in temperate climates,
during the cool rainy season in tropical and subtropical
areas, and during the cool dry season in South America
and South Africa [2]. A study in the US in the mid-nineties
estimated that around 10% of children have bronchiolitis
in the first year of life [3]. However, this estimate for Can-
ada in 2003 was around 4% [4].
Hospital admission rates for bronchiolitis in the US and
Europe are reported to be around 3% for children less
than 1 year of age [2]. Independent factors typically asso-
ciated with a high risk of hospitalization are male gender,
premature birth without or, especially, with broncho-dis-
plasya, congenital heart disease, T-cell immunodeficiency,
age <6 months, birth during the first half of the influenza
season, and crowding/siblings [5,6].
It has been estimated that the respiratory syncytial virus
(RSV) is the etiologic agent in more than 70% of the cases
(80%-90% during the winter) [7]. A study in the mid-
nineties evaluated the safety and efficacy of Palivizumab,
a humanized murine monoclonal anti-F glycoprotein
antibody preparation, in preterm infants with and in
those without chronic lung disease. The study showed the
preparation to be safe and efficacious in reducing RSV-
associated hospitalizations by 55% [8]. A subsequent
study conducted between 1998-2002 in infants ≤ 24
months of age with documented hemodynamically signif-
icant congenital heart disease (CHD) showed a 45% rela-
tive reduction in RSV-associated hospitalizations [9].
Palivizumab was introduced in Italy in 1999 and it is
administered following international and national guide-
lines [10-12]: at-risk children are identified by the neona-
tologists in the perinatal units, their families are then
contacted and offered the prophylaxis free of charge. The
proposed schedules repeat administrations every 30 days
during the epidemic period.
Until now, several studies have evaluated the impact of
introducing Palivizumab prophylaxis on the incidence of
hospitalization with bronchiolitis [13-17] but none of
these have been conducted in Italy. The objectives of this
study were thus to evaluate the incidence rate and factors
associated with preterm infant hospitalizations for bron-
chiolitis, and the use and the impact of Palivizumab in
this country.
Methods
Study design, setting, participants, and data sources
This is a retrospective longitudinal study of preterm
infants (i.e., <36 weeks of gestational age) born between
2000-2006 whose mothers at time of delivery were living
in the catchment area of two local health units (LHUs) in
the Lazio region, central Italy. Both LHUs are located in
the county of Rome, one in the city center and the other
in a suburban area. During the study period the popula-
tion in these two LHUs slightly increased from more than
985,000 at the beginning of 2000 to more than 1,055,000
people at the end of 2006. In this period 67,292 children
were born to resident mothers identified using the birth
register ("Certificati di assistenza al parto" in Italian, here-
after called CEDAP). Details about CEDAP can be found
in previous publications [18,19]. Briefly, this register
reports information on socio-demographic characteristics
of both parents (age, education, occupational status, etc.),
obstetric history and pregnancy (previous pregnancies
and/or abortions, duration, characteristics, etc.) and pre-
natal care (clinical examinations, ultrasounds, amniocen-
tesis, etc.), delivery (place, type, etc.), and information on
the newborn (gender, birth order, birth weight, gesta-
tional age, Apgar score at 5 minutes, etc.). Hospital admis-
sions for bronchiolitis were identified in the hospital
discharge database of the Lazio region ("Sistema Inform-
ativo Ospedaliero della Regione Lazio", hereafter called
SIO). Details about the SIO can be found in previous pub-
lications [20,21]. Briefly, this database was started in 1994
and all hospitals in the region are required to record data
on a standardized form of admission and discharge dates,
personal data of the patient (i.e., date of birth, gender,
name, surname, municipality of residence, nationality),
the principal diagnosis and up to five secondary diagnoses
[coded by the International Classification of Diseases -
ninth revision (ICD-9)], diagnostic procedures (also
coded by the ICD-9), and death, if it occurred during the
hospitalization. Hospitalizations for bronchiolitis were
identified by the ICD-9 code 466.11 or 466.19, reported
either as the first or secondary diagnosis. Although only
code 466.11 refers to bronchiolitis due to VRS, we also
included codes for "other" or "unknown" etiologies. It is
of note that in clinical practice the etiology of bronchioli-
tis is very often not determined because it does not change
the course of treatment in infants. Only subjects hospital-
ized for bronchiolitis before age three were included. The
SIO was also used to identify infants with a diagnosis of
broncho-dysplasia and CHD. It is of note that it is
extremely unlikely that a hospitalization for bronchiolitis
would be missed because SIO covers the entire region, not
only the territory of the LHUs involved.
Data about each single dose of Palivizumab were col-
lected in ad-hoc databases that the two LHUs created for
administrative purposes. In accordance with the nationalBMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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guidelines the prophylaxis was strongly recommended for
children with a gestational age of <32 weeks and aged <1
year at the beginning of the epidemic period. The proph-
ylaxis is also strongly recommended in children with
chronic lung disease and in those with hemodynamically
congenital heart disease (excluding those who had a sur-
gical and radical correction and without need of pharma-
cological treatment) and aged <2 years at the beginning of
the epidemic period. The prophylaxis was also recom-
mended for infants born between 32 and 35 weeks, for
those aged <1 year at the beginning of the epidemic
period and for those with at least two more known risk
factors associated with the disease (e.g., exposure to pas-
sive smoking, not breastfed). If the child was hospitalized,
the prophylaxis was offered at the hospital. After dis-
charge, the public pediatric ambulatory, warned by the cli-
nicians, contacts the family if prophylaxis is indicated for
the infant. Prophylaxis was usually repeated once a month
during the epidemic period.
Cross linkage of the data sources
Data from the various sources were initially linked using
the complete surname, name, gender and date of birth of
the child. This link was performed using the SAS program
(version 8.2). For subjects not linked using those criteria,
the SALI (software for automated linkage in Italy) pro-
gram was used to match individual records. SALI reduces
false negatives by taking into account possible errors in
key fields [22]. Finally, for immunized children and for
children hospitalized for bronchiolitis not linked with
CEDAP after the previously described automated cross-
linkages, the CEDAP was checked manually for all chil-
dren born on the date of birth of any immunized or hos-
pitalized child unidentified in the previous steps.
Statistical analysis
The analysis initially included 2558 children born
between 2000-2006 in the two LHUs for whom the
reported gestational age in the CEDAP was <36 weeks. We
then excluded 151 of them whose date of discharge after
delivery was after 31/12/2006 or not listed, or the gender
was not reported, or who died immediately after birth.
The outcome of the analysis was initially any hospitaliza-
tion for bronchiolitis within the first three years of age.
However, the analysis we conducted was restricted to first
hospitalizations within the first 18 months, because only
six cases had more than one hospitalization for bronchi-
olitis and only two cases were hospitalized after 18
months of age. The incidence rate was calculated as the
ratio of the hospitalizations for bronchiolitis within 18
months of age out of the person-time at risk. For each
child, the person-time at risk was calculated from the date
of discharge after delivery until the first hospitalization for
bronchiolitis, the date the child turned 18 months of age,
and the first of January 2007. Incidence rates of hospitali-
zation for bronchiolitis were also calculated stratifying for
several of the infants' characteristics at birth [i.e., birth
weight (<1000, 1000-2000, >2000 grams), gestational age
(<32, 32-36 weeks), gender, year of birth, Apgar score at 5
minutes after birth (≤ 7, >7), reported diagnosis of bron-
cho-dysplasia during the delivery hospitalization or in
subsequent hospitalizations (ICD9-CM code: 770.7 in
any diagnostic position], reported diagnosis of CHD at
delivery or at subsequent hospitalizations (ICD9-CM
codes: 745.0, 7451.10, 745.11, 745.2, 745.3, 745.69,
746.01, 746.02, 746.1, 746.2, 746.7, 746.89, 747.22,
747.3 in any diagnostic position)] and of maternal char-
acteristics [i.e, age at delivery (i.e.,≤ 32, >32 years, where
32 is the median age), years of education (≤ 8 years, >8
years, unknown), country of birth (Italy, other), and par-
ity (0,1, ≥ 2)]. Incidence rates were also calculated stratify-
ing for age of the infants (i.e. in months and into three
groups: <6, 6-11, 12-18 months) and calendar month.
Crude and adjusted incidence rate ratios (IRR) of bronchi-
olitis hospitalizations for the previously described charac-
teristics were estimated using univariate and multiple
Poisson models.
Descriptive frequency tables of the previously described
characteristics and use of Palivizumab were provided. To
evaluate the association of some characteristics with Pal-
ivizumab use we calculated the Chi-squared test. To eval-
uate the independent association of these characteristics
with the administration of Palivizumab, a multiple logis-
tic analysis was performed.
To evaluate the impact of the administration of Palivizu-
mab on the risk of being hospitalized, we performed addi-
tional Poisson models that estimated IRRs for immunized
compared to non-immunized infants using two different
approaches of selecting specific at risk time periods
among those who received prophylaxis. The first
approach evaluated the effectiveness of the immunization
in its entirety considering as the at-risk-time the period
since the date of the first dose of Palivizumab adminis-
tered to the first hospitalization for bronchiolitis, or the
date the subject turned 18 months of age, or the first of
January 2007, whichever comes first (see section A of Fig-
ure 1). This approach evaluated the effect of the immuni-
zation strategy in its entirety and hereafter is referred to as
the vaccination-strategy effectiveness. The second
approach evaluated the specific effect of Palivizumab in
the 30 days after each dose. This means that all time peri-
ods and events 30 days after each dose was administered
were not considered in the analysis. This approach, here-
after referred to as the dose-effectiveness approach, mim-
ics the proposed scheme of administration and it
evaluates the "absolute" effect of the prophylaxis only in
the 30 days following each administration (see section BBMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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of Figure 1). For both approaches a multiple Poisson
model, including the previously described characteristics
as possible confounders, was performed. Furthermore,
this model was also performed 1) restricting only to chil-
dren born at <32 weeks gestation; 2) restricting the analy-
sis to the time periods from the beginning of October to
the end of April (i.e., the epidemic period) of each year.
The analyses about the effectiveness of Palivizumab were
restricted to the first year of life as this prophylaxis is not
recommended after one year of age in most preterm
infants without chronic lung disease.
Study approval
Lazio Sanità-Agenzia di Sanità Pubblica is the governmen-
tal agency of the Lazio region responsible for health infor-
mation systems (e.g., infectious disease notifications,
hospital discharge records); the management of these data
for public health purposes does not require a patient's
informed consent nor it does require any authorization
regarding privacy laws.
Results
Incidence and risk factors of hospitalization for 
bronchiolitis
During the period 2000-2006, 67,292 children were born
to mothers living in the two LHUs of Rome; the median
gestational age was 39 (mean = 38.9) weeks. Among
them, 2407 (3.6%) were born at <36 weeks of gestation;
the median gestational age among preterm infants was 34
(mean = 33) weeks and 201 (8.3% of preterm infants)
were born at <29 weeks.
Table 1 shows the number of cases, the person-years and
the incidence rates of a first hospitalization for bronchi-
olitis by age, by calendar month, and by calendar year
among preterm infants. One hundred thirty-seven were
hospitalized at least once with a diagnosis of bronchiolitis
within the first 18 months of age. Overall, the incidence
rate was 4.70 per 100 person-years (PY) (95%CI: 3.98-
5.56). Significantly higher incidence rates were observed
in the first six months of life and the incidence rates
Graphical representation of how person-time at risk of being hospitalized for bronchiolitis was calculated for non-prophylaxed  and prophylaxed infants Figure 1
Graphical representation of how person-time at risk of being hospitalized for bronchiolitis was calculated for 
non-prophylaxed and prophylaxed infants. For prophylaxed infants, two different approaches were proposed. Box A 
shows that person time was calculated since the first date of Palivizumab administration to the first hospitalization for bronchi-
olitis, or the date the subject turned 18 months of age, or the first of January 2007, whichever comes first. Box B shows that, 
compared to the previous approach, the person-time does not include the time-periods exceeding the 30 days after each Paliv-
izumab administration. In this case also hospitalizations for bronchiolitis happened in the dashed periods are not considered.
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decreased with age (p < 0.01). This significantly decreas-
ing trend was also observed by month of age (Figure 2,
section A) (p < 0.01). Incidence rates also varied signifi-
cantly by calendar month with the highest rates observed
in the period October-April (hereafter defined as the epi-
demic period), with a peak in January (Figure 2, section
B); the incidence rate was 7.17 and 1.22 per 100 PY in the
epidemic and in the non-epidemic period (p < 0.01),
respectively. Table 2 shows the incidence rates of a first
hospitalization for bronchiolitis stratified for several char-
acteristics. Significant higher incidence rates were
observed for children born to mothers with ≤ 8 years of
education compared to those with >8 years (p = 0.02).
Characteristics of the infants that were significantly asso-
ciated with higher incidence rates included: male gender
(p = 0.02), low birth weight (p < 0.01), gestational age
<32 weeks (p = 0.01), Apgar score ≤ 7, and presence of
bronchodysplasia (p = 0.04); there was no statistical sig-
nificance for year of birth (p = 0.61).
Table 3 shows the crude (CIRR) and adjusted incidence
rate ratios (AIRR) of being hospitalized for bronchiolitis.
After adjusting for all characteristics, statistically signifi-
cant higher risks were still found for children born to
mothers with ≤ 8 years of education, for males, in the first
months of age, for low birth weight infants, for children
with an Apgar score ≤ 7, and in the epidemic period. Sim-
ilar results were found performing other Poisson models
where birth weight and gestational age were entered as
categorical instead of continuous variables (data not
shown in table).
Use of Palivizumab and estimates of its effectiveness on 
the risk of hospitalization for bronchiolitis
Overall, 324 (13.5%) children received at least one dose
of Palivizumab. There were 1291 doses administered with
a median of 4 doses received per child. Doses were admin-
istered exclusively between October and April, with the
mode of administration in December (24.7% of the
total). Table 4 shows maternal and infant characteristics
stratified for Palivizumab use (i.e., no administration and
at least one dose). During the study period, the percentage
of children who received Palivizumab dramatically
increased from 2.8% in 2000 to 19.1% in 2006. Palivizu-
mab was more frequently administered to children born
to mothers over 32 years of age, who had no other chil-
dren, more than 8 years of education, and who were born
in Italy; regarding the characteristics of the infants; Palivi-
Table 1: Incidence rates of hospitalization for bronchiolitis in the first 18 months of age in premature infants, Rome, Italy, 2000-2006
Person years
(PY)
Cases Rate
(per 100 PY)
95% CI
Age (months)
[0 -- 6] 986 88 8.93 7.24 -11.00
(6 - 12] 1005 42 4.18 3.09 -5.65
(12 - 18] 921 7 0.76 0.36 -1.59
Calendar month
January 223 25 11.20 7.57 -16.57
February 226 24 10.64 7.13 -15.87
March 227 14 6.18 3.66 -10.43
April 229 12 5.23 2.97 -9.21
May 235 4 1.70 0.64 -4.54
June 238 3 1.26 0.41 -3.90
July 245 2 0.82 0.20 -3.27
August 251 3 1.20 0.39 -3.71
September 254 3 1.18 0.38 -3.66
October 257 12 4.67 2.65 -8.22
November 262 18 6.88 4.33 -10.91
December 266 17 6.39 3.98 -10.29
Year of observation
2000 138 7 5.07 2.42 -10.63
2001 399 17 4.26 2.65 -6.85
2002 427 22 5.15 3.39 -7.82
2003 436 30 6.88 4.81 -9.84
2004 503 18 3.58 2.25 -5.68
2005 527 23 4.36 2.90 -6.56
2006 481 20 4.16 2.68 -6.44
Total 2912 137 4.70 3.98 -5.56BMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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zumab was more frequently administered to females, with
a birth weight of <1000 grams, who were born at <32
weeks, with an Apgar score of ≤ 7, with a diagnosis of
bronchodysplasia, and to those born between July and
December. It is of note that Palivizumab was not admin-
istered to infants with CHD. Among them, only 5
(14.7%) were born at <32 weeks of gestation, while 8
(23.5%) and 15 (44.1%) were born at 34 and 35 weeks,
respectively. Multiple logistic regression showed statisti-
cally significant adjusted odds-ratio (AOR) >1 of receiving
Palivizumab for preterm infants born to mothers >32
years old, for those born to Italian mothers, for females,
for those born most recently, for those who weighed
<2000 grams, for those born at <32 weeks, for those with
an Apgar score ≤ 7, for those not born in the spring, and
for those with a diagnosis of bronchodysplasia.
Among the 324 preterm children who received at least
one dose of Palivizumab, 8 (2.5%) were hospitalized with
bronchiolitis in the first 12 months of life. Among them,
6 were hospitalized in the 30-day period just after each
administration of Palivizumab. The incidence rate was
5.72 (95%CI: 2.86-11.44; PY = 140) per 100 PY, slightly
lower than that observed in non-immunized children
(6.97 per 100 PY, 95%CI: 5.84-8.32; PY = 1751). The inci-
dence rate in the 30 days immediately after each adminis-
tration of Palivizumab was 9.55 (95%CI: 4.29-21.27; PY
= 63) per 100 PY. Table 5 shows the estimated crude and
adjusted IRRs of hospitalization for bronchiolitis for
those who received Palivizumab compared to those who
did not, estimated by several Poisson models and with the
two different approaches (see methods and figure 1).
When adjusting for potential confounders, no significant
risk reductions were found in th eproposed models, but
one (i.e., Model 2, vaccination-strategy).
Discussion
We evaluated the incidence and the risk factors of hospi-
talization for bronchiolitis in preterm children in and
around Rome, Italy. Overall, the incidence of hospitaliza-
tion was 4.70 per 100-PY in the first 18 months of age and
this estimate is in agreement with that reported in other
studies [6,16,23,24]. We found that the incidence strongly
declined with age and that hospitalization after 18
months of age is extremely rare. Furthermore, we
observed a strong seasonal effect with the highest
monthly incidence estimated from October to April.
Other independent significant risk factors of being hospi-
talized for bronchiolitis were: low Apgar score 5 minutes
after birth, low birth weight, male gender, and low educa-
tional level of the mother (i.e., ≤ 8 years). While our
results for some of these factors (i.e., young age, autumn/
winter period, low birth weight, low Apgar score, and
male gender) are in agreement with previous publications
[2,5,6], low educational level has never before been iden-
tified as an independent risk factor for hospitalization for
Table 2: Incidence rates of first hospitalization for bronchiolitis in the first 18 months of age in premature infants, stratified for several 
characteristics, Rome, Italy, 2000-2006
NP e r s o n
Years (PY)
Cases Rate
(per 100 PY)
95% CI
Age of the mother (years) ≤ 32 1119 1359.4 68 5.00 3.94 -6.34
>32 1288 1553.1 69 4.44 3.51 -5.63
Parity 0 1457 1773.2 77 4.34 3.47 -5.43
1 679 807.77 45 5.57 4.16 -7.46
≥ 2 271 331.55 15 4.52 2.73 -7.50
Years of education ≤ 8 1085 1312.5 80 6.10 4.90 -7.59
>8 1318 1597 56 3.51 2.70 -4.56
Unknown 4 3 1 33.33 4.70 -236.64
Birth-country of the mother Italy 2049 2505 119 4.75 3.97 -5.68
Other 358 407 18 4.42 2.79 -7.02
Gender Males 1282 1535.2 85 5.54 4.48 -6.85
Females 1125 1377.3 52 3.78 2.88 -4.95
Birth weight (grams) <1000 152 161.96 15 9.26 5.58 -15.36
1000-2000 786 911.71 60 6.58 5.11 -8.48
>2000 1469 1838.8 62 3.37 2.63 -4.32
Gestational age <32 516 585.24 34 5.81 4.15 -8.13
32-35 1891 2327.3 103 4.43 3.65 -5.37
Apgar score ≤ 7 395 456 36 6.57 4.74 -9.11
>7 2012 2456 101 3.43 2.82 -4.17
Broncho dysplasia No 2346 2850 131 4.60 3.87 -5.46
Yes 61 63 6 9.54 4.29 -21.24
Congenital heart disease No 2373 2873 134 4.66 3.94 -5.52
Yes 34 40 3 7.58 2.44 -23.50BMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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bronchiolitis. This could be a proxy of other factors, such
as maternal smoking that was not evaluated in our study.
It is of note that other factors, such as increasing birth
order, a diagnosis of bronchodysplasia, CHD, and low
gestational age, after having adjusted for the other covari-
ates, were not significantly associated with being hospital-
ized for bronchiolitis, and this contrasts with previous
publications [2]. The results regarding gestational age can
be explained by their strong correlation with low birth
weight; regarding increasing birth order, bronchodyspla-
sia, and CHD, the estimated adjusted IRR still suggest that
children with these characteristics had a greater risk of
being hospitalized with bronchiolitis, and the fact that
they were not found to be statistically significant is likely
only the result of the limited statistical power due to the
low numbers in these groups.
During the 2000-2006 study period we observed a signif-
icantly increasing trend of the percentage of pre-term chil-
dren who received at least one dose of Palivizumab. After
adjusting for other covariates, year of birth was still
strongly associated with the administration of Palivizu-
mab; other factors independently associated were low
birth weight, shorter gestation, low Apgar score, reported
diagnosis of bronchodysplasia, female gender, birth coun-
try and maternal age. While the first four factors were
expected to be associated with Palivizumab prophylaxis,
there is no clear explanation for the latter three. In partic-
ular, it was expected that male children, being at higher
risk of hospitalization, were more likely to have received
prophylaxis with Palivizumab than females and not vice
versa. One possible explanation could be related to
unknown, uncontrolled confounders for which the effect
was indirectly expressed through gender [25]. Regarding
maternal age and maternal birth country, the lower
adjusted odds of receiving at least one dose of Palivizu-
mab could reflect, as a proxy, lower social economic sta-
tus. Furthermore, for mothers born outside Italy there
could have been difficulties for the LHUs in contacting or
in communicating with them.
We evaluated if there was a risk reduction of hospitaliza-
tion for bronchiolitis in infants who received at least one
dose of Palivizumab with two different analyses trying to
Incidence rates of hospitalizations for bronchiolitis by age (in months) (section A) and by calendar month (section B) in pre- term infants; Rome, Italy 2000-2006 Figure 2
Incidence rates of hospitalizations for bronchiolitis by age (in months) (section A) and by calendar month (sec-
tion B) in pre-term infants; Rome, Italy 2000-2006.
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identify both the effectiveness of each single dose and of
the scheduled immunization program offered. In both
cases we did not find, using different multiple models and
different selected populations, a signficant risk reduction,
but in one model (Model 2, Vaccination strategy in Table
5). However, all proposed models have point estimates
that are similar ranging between 33% and 53% in Table 5.
Although our estimates of the risk reduction were a little
bit lower than the two clinical trials performed [8,9], we
cannot exclude that this different magnitude of the effect
simply resulted from chance. Furthermore, it is of note
that the all hospitalizations studied in the two clinical tri-
als had RSV antigen positive tests while we studied any
hospitalization for bronchiolitis independent of RSV test
results. As we specified in the methods section, the identi-
fication of the etiological agent of bronchiolitis in clinical
practice is not always performed because it does not
change the type of treatment given. Assuming that RSV-
related hospitalizations for bronchiolitis were, as reported
in the literature [2], 70% of the total, and that Palivizu-
mab does not have any effect on non-RSV-related cases of
bronchiolitis, we can further reduce our estimates of the
effectiveness of Palivizumab on bronchiolitis hospitaliza-
tions of 30%. This implies that our risk reduction esti-
mates of hospitalizations for RSV-related bronchiolitis
should range between 53% and 67%, very similar to those
previously reported in the two clinical trials.
It is of note that our data did not show any impact on the
trend of the hospitalizations for bronchiolitis as shown by
the incidence rates and the adjusted IRR by calendar year
(see table 2 and 3). Even though the use of Palivizumab
dramatically increased between 2000 and 2006, less than
20% of the preterm children born between 2004 and
2006 received the prophylaxis and the expected number
of cases that were prevented is very low.
Before drawing conclusions we should consider some lim-
itations of this study. First, this study was based on data
collected only by two LHUs and results are limited by the
small study size. Second, this was a retrospective observa-
tional study and the measured characteristics for children
at birth, the date of Palivizumab administration, and the
hospitalizations were taken from large databases created
for other purposes. Third, we identified bronchiolitis hos-
pitalizations using the ICD9-CM diagnostic codes 466.11
or 466.19. It is of note that in many cases the code 466.19
(bronchiolitis associated to a non-RSV or unknown infec-
tious agent) was reported in the hospital discharge form;
this most likely occurred because no diagnostic exams had
been performed to identify the underlying infectious
agent. This did not permit us to perform specific analyses
of RSV-associated bronchiolitis. However, many studies
reported that between 70% and 90% of hospitalizations
for bronchiolitis in infants are RSV-associated (2). Finally,
preterm infants have a high risk of death and we cannot
exclude that for some of them we could have overesti-
mated the person-time at risk of broncholitis if they died
before 18 months of age. However, since we excluded
those who died during their first hospital admission the
impact of this issue on our results should be limited.
Table 3: Crude (CIRR) and adjusted (AIRR) incidence rate ratios of hospitalization for bronchiolitis, Rome, Italy 2000-2006
CIRR (95% CI) p-value AIRR (95% CI) p-value
Age of the mother (years) ≥ 32 vs. <32 1.13 (0.80 -1.58) 0.49 1.08 (0.75 -1.55) 0.67
Parity 1 vs. 0 1.28 (0.88 -1.86) 0.19 1.34 (0.91 -1.98) 0.14
≥ 2 vs. 0 1.04 (0.59 -1.83) 0.89 1.09 (0.60 -1.95) 0.78
Years of education ≤ 8 vs. >8 1.74 (1.23 -2.46) <0.01 1.71 (1.18 -2.48) 0.01
Not known vs. >8 9.51 (0.88 -102.1) 0.06 9.82 (0.79 -122.4) 0.08
Birth country of the mother Italy vs. other 1.07 (0.65 -1.78) 0.78 1.30 (0.73 -2.30) 0.37
Gender  male vs female 1.47 (1.03 -2.08) 0.03 1.48 (1.04 -2.10) 0.03
Calendar year (ref. 2001) 2000 1.19 (0.49 -2.86) 0.70 0.79 (0.33 -1.88) 0.60
2002 1.21 (0.64 -2.28) 0.56 1.28 (0.68 -2.43) 0.44
2003 1.61 (0.89 -2.93) 0.12 1.73 (0.95 -3.16) 0.07
2004 0.84 (0.43 -1.63) 0.61 0.92 (0.47 -1.79) 0.81
2005 1.02 (0.54 -1.92) 0.94 1.24 (0.66 -2.34) 0.50
2006 0.98 (0.51 -1.87) 0.94 1.16 (0.60 -2.24) 0.66
Age (months) <6 vs. ≥ 12 11.75 (5.44 -25.35) <0.01 14.54 (6.75 -31.35) <0.01
6-11 vs. ≥ 12 5.50 (2.47 -12.24) <0.01 5.98 (2.68 -13.35) <0.01
Epidemic period Yes vs. No 5.89 (3.44 -10.06) <0.01 5.48 (3.22 -9.35) <0.01
Birth weight  per 100 g decrease 1.05 (1.02 -1.07) <0.01 1.06 (1.02 -1.11) 0.01
Gestational age per 1 week less 1.08 (1.02 -1.14) 0.01 0.97 (0.88 -1.07) 0.58
Apgar score ≤ 7 vs. > 7 2.06 (1.40 -3.03) <0.01 1.57 (0.99 -2.48) 0.05
Broncho-dysplasia Yes vs. No 2.08 (0.91 -4.75) 0.08 1.70 (0.68 -4.28) 0.26
Congenital heart disease Yes vs. No 1.63 (0.51 -5.18) 0.41 1.64 (0.52 -5.19) 0.40BMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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Table 4: Use of Palivizumab in preterm infants and adjusted odds ratios (AOR) by several characteristics; Rome, Italy 2000-2006
Yes p value AOR (95%CI) p
value
N %
Age of the mother (years) ≤ 32 (REF) 118 10.5 <0.01 1.00 <0.01
>32 206 16.0 1.67 (1.22 -2.30)
Parity 0 (REF) 221 15.2 <0.01 -
1 72 10.6 0.83 (0.58 -1.18) 0.30
>1 31 11.4 0.92 (0.55 -1.54) 0.74
Years of education of the mother ≤ 8 years (REF) 137 12.6 0.20 1.00 -
>8 years 186 14.1 1.14 (0.84 -1.54) 0.42
Not known 12 5 . 0 N E -
Country of birth of the mother Italy (REF) 283 13.8 0.23 1.00 - <0.01
Other 41 11.4 0.47 (0.30 0.73)
Gender Male (REF) 160 12.5 0.13 1.00 -
Female 164 14.6 1.34 (1.00 1.80) 0.05
Year of birth 2000 (REF) 9 2.8 <0.01 1.00 -
2001 22 7.0 2.48 (1.02 -6.00) 0.04
2002 41 13.0 7.00 (3.05 -16.02) <0.01
2003 47 13.0 9.37 (4.13 -21.28) <0.01
2004 73 18.4 13.88 (6.23 -30.93) <0.01
2005 61 18.3 17.90 (7.87 -40.67) <0.01
2006 71 19.1 18.43 (8.19 -41.46) <0.01
Birth weight (grams) <1000 (REF) 76 50.0 <0.01 1.00 -
1000-2000 209 26.6 1.22 (0.75 -1.99) 0.42
>2000 39 2.6 0.18 (0.10 -0.34 <0.01
Gestational age (weeks) <32 (REF) 221 42.8 <0.01 1.00 -
32-35 103 5.4 0.19 (0.13 -0.27) <0.01
Bronchodysplasia Yes (REF) 41 67.2 <0.01 5.96 (2.90 -12.26) <0.01
No 283 12.1 -
Apgar score ≤ 7 128 32.4 <0.01 1.55 (1.10 -2.19) 0.01
>7 (REF) 196 9.7 -
Month of birth Jan-Mar 71 12.6 <0.01 1.57 (1.00 -2.45) 0.05
Apr-Jun (REF) 68 11.4 1.00 -
Jul-Sep 99 15.3 2.00 (1.32 -3.03) <0.01
Oct-Dec 86 14.4 2.12 (1.38 -3.26) <0.01
Congenital heart disease (CHD) Yes (REF) 0 0.0 0.02 1.00 -
No 324 13.6 NE -
Total 324 13.5
AOR: Adjusted odds ratio of administration of Palivizumab; REF: reference group; NE: not estimable
Table 5: Incidence rate ratios (IRR) of hospitalization for bronchiolitis in preterm infants immunized compared to those not 
immunized with Palivizumab, Rome, Italy 2000-2006
Vaccination-dose effectiveness Vaccination-strategy effectiveness
IRR 95% CI p-value IRR 95% CI p-value
Model 1: univariate analysis 1,37 0,60 -3,11 0,45 0,82 0,40 -1,69 0,59
Model 2: multiple analysis* 0,51 0,22 -1,17 0,11 0,47 0,23 -0,98 0,04
Model 3: as model 2 but restricted to GA<32 weeks  0,67 0,24 -1,85 0,44 0,65 0,26 -1,63 0,36
Model 4: as model 2 but restricted only to the epidemic 
period
0,50 0,22 -1,14 0,10 0,49 0,24 -1,03 0,06
*adjusted for all covariates of table 3; GA = Gestational ageBMC Pediatrics 2009, 9:56 http://www.biomedcentral.com/1471-2431/9/56
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Conclusion
In conclusion, this is the first report since the introduction
of Palivizumab to evaluate the incidence and risk factors
associated with hospitalizations for bronchiolitis in pre-
term infants in Italy. We highlighted that in Italy the inci-
dence of hospitalization for bronchiolitis and the risk
factors associated with it are similar to those found in
other countries. Although the use of Palivizumab is asso-
ciated with the most important characteristics of severe
prematurity, its non-use in children with congenital heart
disease contrasts with international guidelines; further-
more, its association with maternal age and the country of
birth suggests the need for public health measures that can
reduce health disparities.
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